non progressors

Related by string. * nOn . NON . nons . - - Non . Non : Non GAAP Financial . non farm payrolls . Non Aligned Movement NAM . Non GAAP net . Non Brokered Private Placement . Non Brokered BULLETIN DATE . Non GAAP Measures . Non performing . Non GAAP Adjustments . Non Governmental Organisations NGOs . non English curse . Non GAAP EPS . non . non coding RNAs / : progressors . slow progressors * *

Related by context. Frequent words. (Click for all words.) 62 androgen deprivation 58 viremia 57 virologic failure 56 CMV infection 56 telomerase activity 56 coinfected 55 virologic response 55 elevated CRP 55 sustained virologic response 54 grade gliomas 54 KRAS mutations 54 latent TB infection 54 HBV infection 53 HCV infected 53 noncarriers 53 subclinical 53 BRAF mutation 53 peginterferon 52 immunosuppression 52 neutralizing antibody 52 RRMS patients 52 Hepatitis B virus 52 familial hypercholesterolemia 52 hydroxychloroquine 52 serum concentrations 52 viral suppression 52 Median survival 52 sulfasalazine 52 heavily pretreated 52 APOE4 52 telomere shortening 52 glucocorticoids 52 serum calcium 52 poorer prognosis 52 multidrug resistance 52 mycophenolate mofetil 51 HSCT 51 amenorrhea 51 % CI #.#-#.# [003] 51 seropositive 51 lymphopenia 51 decitabine 51 lipid lowering therapy 51 CMV disease 51 interferon therapy 51 ApoE4 51 Ebola hemorrhagic fever 51 biochemical recurrence 51 chronic hepatitis 51 grade dysplasia 51 EGFR mutation 51 complete remissions 51 liver transplant recipients 51 CLL cells 51 shorter telomeres 51 Genital herpes 51 ± SD 51 Combination therapy 51 BRCA2 mutations 51 VZV 50 % CI #.#-#.# [007] 50 tamoxifen therapy 50 undetectable viral load 50 cytogenetic response 50 telomere length 50 BRCA mutations 50 HCV infection 50 pheochromocytoma 50 latent infection 50 adefovir 50 interferon alfa 50 IGFBP 3 50 fulvestrant 50 complete cytogenetic 50 anticoagulant therapy 50 cystectomy 50 EGFR mutations 50 PlGF 50 median PFS 49 Natalizumab 49 undetectable HCV RNA 49 COPAXONE ® 49 transplanted kidneys 49 superficial bladder cancer 49 untreated mice 49 fasting glucose levels 49 estrogen receptor negative 49 null responders 49 antibody responses 49 acting beta agonists 49 nucleoside analogue 49 NNRTIs 49 concomitant medications 49 asymptomatic 49 mg kg dose 49 seroprotection 49 reperfusion therapy 49 lung fibrosis 49 lupus nephritis 49 IFN gamma 49 mRCC

Back to home page